Drugs / amoxicillin/clavulanate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00914888 Comparator | Jan 2011 → May 2014 | bacterial pneumonia | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amoxicillin/clavulanate | “on or after Day 4 amoxicillin/clavulanate may be prescribed” NCT00914888 ↗ |
| Route | Oral | “Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed” NCT00914888 ↗ |